Protagenic swings to FY26 net income of $1.37 million; operating expenses rise 74% to $4.5 million

• Protagenic posted GAAP net income of $1.37 million, swinging from a net loss a year earlier.
• Total operating expenses rose 74% to $4.5 million, led by higher R&D spending and legal fees.
• Net cash used in operating activities widened 59% to $2.81 million; cash was $1.51 million with working capital of $511,107.
• Pipeline reset followed an unwind of the Phytanix Bio reverse merger; the company paid $300,000 at closing plus $10,000 later.
• Management sees cash funding operations until about the end of Q3 2026; PT00114 timelines target Phase Ib in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038255), on August 14, 2026, and is solely responsible for the information contained therein.